Who is sponsoring NCT03604965?

NCT03604965 is sponsored by Guiyang Medical University.

What drugs are being tested in NCT03604965?

Interventions in NCT03604965: GP+CCRT, TPF+CCRT.

What condition does NCT03604965 study?

NCT03604965 studies Locally Advanced Nasopharyngeal Carcinoma.

Is NCT03604965 still recruiting?

NCT03604965 is currently status unknown. Last updated 30 July 2018.

Last reviewed 2018-07-30 · How we verify

NCT03604965

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC

Status unknown Phase 3 Last updated 30 July 2018

What this trial tests

Phase 3 trial testing GP+CCRT in Locally Advanced Nasopharyngeal Carcinoma in 204 participants. Status unknown.

Timeline

21 July 2018

Primary endpoint
21 July 2020

21 July 2020

Quick facts

Lead sponsor	Guiyang Medical University
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	204
Start date	21 July 2018
Primary completion	21 July 2020
Estimated completion	21 July 2020
Sites	1 location across China

Drugs / interventions tested

GP+CCRT — full drug profile →
TPF+CCRT — full drug profile →

Conditions studied

Locally Advanced Nasopharyngeal Carcinoma — all drugs for Locally Advanced Nasopharyngeal Carcinoma →

Sponsor

Guiyang Medical University

Who can join

Adults 18 to 69, any sex, with Locally Advanced Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through randomized controlled phase III multicenter clinical trials, GP induction chemotherapy vs TPF regimen adjuvant chemotherapy combined with DDP concurrent chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma: the efficacy, toxicity and quality of life, and further improvement Survival rate and improve the quality of life.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis.
Wang BC, Xiao BY, Lin GH, Wang C, et al · · 2020 · cited 12× · PMID 32375701 · DOI 10.1186/s12885-020-06912-3

Verify or expand the search:

Other trials of GP+CCRT

Trials testing the same drug.

NCT06605131 — GP Combined with Toripalimab Versus GP Induction Chemotherapy for Advanced Childhood Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting

Other recruiting trials for Locally Advanced Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT07085234 — Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC · Phase 2 · recruiting
NCT05892354 — Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy · NA · recruiting
NCT05397769 — Envafolimab Plus Chemoradiotherapy for Locally Advanced NPC, a Prospective, Single Armed Phase II Trial. · Phase 2 · recruiting
NCT05062005 — ICCRT vs. CRT for Locally Advanced Nasopharyngeal Carcinoma · Phase 3 · recruiting

Other Guiyang Medical University trials

Trials by the same sponsor.

NCT03723343 — GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant M · unknown
NCT03557112 — By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio · Phase 2 · unknown
NCT03574324 — TPF Induction Chemotherapy vs PF Adjuvant Chemotherapy Combined With Concurrent Chemoradiotherapy in the Treatment of Lo · Phase 3 · unknown
NCT03196869 — the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasophar · Phase 2 · unknown
NCT03117257 — Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03604965 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guiyang Medical University
Last refreshed: 30 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03604965.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing